Factory selling USP EP BP 99% API Lidocaine base , Lidocaine HCL powderin stock with safe shipping way CAS NO.: 137-58-6

Superiority:

Factory selling USP EP BP 99% API Lidocaine base , Lidocaine HCL powderin stock with safe shipping way CAS NO.: 137-58-6

Product name: Lidocaine

Cas number: 137-58-6

Appearance and properties: white crystal powder

Density: 1.026g/cm3

Melting point: 66-69 C: C at 760mmHg

Boiling point of 350.8 degrees 166 degrees

Flash point: 166 degrees

Water solubility: practically insoluble

Stable: strong oxidizing agents

Storage conditions: n a dry: Store cool, place. Keep container closed when not in use.

Vapor pressure: 4.28E-05mmHg at 25 C

Lidocaine hydrochloride is a white crystalline powder which is soluble in water and has the same toxicity as procaine. However, local anesthesia has a strong and lasting effect. It has good surface penetration, can be injected and can also be used as surface anesthesia. Lidocaine is a very good local anesthetic, usually one to three minutes after the effective, the effect remained for one to three hours. Used in the treatment of oral ulcers. It is no longer used as an antiarrhythmic drug, because it is feared that it will have long-term side effects. A small number of people are allergic to lidocaine

Description

Lidocaine, xylocaine, or lignocaine is a common local anesthetic and class-1b antiarrhythmic drug. Lidocaine is used topically to relieve itching, burning, and pain from skin inflammations, injected as a dental anesthetic, or as a local anesthetic for minor surgery.It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic healthcare system.

Lidocaine is the most important class-1b antiarrhythmic drug; it is used intravenously for the treatment of ventricular arrhythmias (for acute myocardial infarction, digoxin poisoning, cardioversion, or cardiac catheterization) if amiodarone is not available or contraindicated.

Lidocaine should be given for this indication after defibrillation, CPR, and vasopressors have been initiated. A routine prophylactic administration is no longer recommended for acute cardiac infarction; the overall benefit of this measure is not convincing.

Application

The efficacy profile of lidocaine as a local anesthetic is characterized by a rapid onset of action and intermediate duration of efficacy. Therefore, lidocaine is suitable for infiltration, block, and surface anesthesia. Longer-acting substances such as bupivacaine are sometimes given preference for subdural and epidural anesthesias; lidocaine,though, has the advantage of a rapid onset of action.

Relative insensitivity to lidocaine is genetic.In hypokalemic sensory overstimulation, relative insensitivity to lidocaine has been described in people who also have attention deficit hyperactivity disorder.In dental anesthesia, a relative insensitivity to lidocaine can occur for anatomical reasons due to unexpected positions of nerves. Some people with Ehlers-Danlos syndrome are insensitive to lidocaine.

Lidocaine, along with ethanol, ammonia, and acetic acid, has also been proven to be effective in treating jellyfish stings, both numbing the affected area and preventing further nematocyst discharge.